A Study of the Safety and Pharmacology Of PI3-Kinase Inhibitor GDC-0941 In Combination With Either Paclitaxel And Carboplatin (With or Without Bevacizumab) or Pemetrexed, Cisplatin, And Bevacizumab in Patients With Advanced Non Small Cell Lung Cancer

• Incidence, nature, and severity of adverse events [ Time Frame: Through study completion or early study discontinuation ] [ Designated as safety issue: No ]
• Tumor response [ Time Frame: Assessed at periodic intervals ] [ Designated as safety issue: No ]

• Incidence, nature, and severity of adverse events [ Time Frame: Through study completion or early study discontinuation ]
• Tumor response [ Time Frame: Assessed at periodic intervals ]

This is an open-label, multicenter, Phase Ib dose-escalation study to assess the safety, tolerability, and pharmacokinetics of oral (PO) GDC-0941 administered with one of three planned regimens: Arm A: paclitaxel and carboplatin in bevacizumab-ineligible NSCLC patients, Arm B: paclitaxel, carboplatin, and bevacizumab in bevacizumab-eligible NSCLC patients and Arm C: pemetrexed, cisplatin, and bevacizumab in bevacizumab-eligible, non-squamous NSCLC patients.

• Drug: bevacizumab
  Intravenous repeating dose
• Drug: carboplatin
  Intravenous repeating dose
• Drug: GDC-0941
  Oral repeating dose
• Drug: paclitaxel
  Intravenous repeating dose
• Drug: pemetrexed
  Intravenous repeating dose
• Drug: cisplatin
  Intravenous repeating dose

• Experimental: A
  Interventions:

  • Drug: carboplatin
  • Drug: GDC-0941
  • Drug: paclitaxel
• Experimental: B
  Interventions:

  • Drug: bevacizumab
  • Drug: carboplatin
  • Drug: GDC-0941
  • Drug: paclitaxel
• Experimental: C
  Interventions:

  • Drug: bevacizumab
  • Drug: GDC-0941
  • Drug: pemetrexed
  • Drug: cisplatin

Inclusion Criteria:

• Histologically or cytologically documented NSCLC with advanced disease (Stage IIIb not eligible for chemoradiotherapy or Stage IV or recurrent disease)
• Adequate organ function as assessed by laboratory tests
• Evaluable disease or disease measurable per Response Evaluation Criteria in Solid Tumors (RECIST)

Exclusion Criteria:

• More than one anti-cancer regimen (chemotherapy or radiotherapy) for advanced NSCLC prior to initiation of study treatment
• Any adjuvant or neoadjuvant anti-cancer therapy within a specified timeframe prior to first study treatment
• History of Grade >= 3 fasting hyperglycemia or diabetes requiring regular medication
• Active autoimmune disease, active infection requiring IV antibiotics, or other current uncontrolled illness
• History of clinically significant cardiac or pulmonary dysfunction
• History of malabsorption syndrome or other condition that would interfere with enteral absorption
• Clinically significant history of liver disease
• Any condition requiring full-dose anticoagulants, such as warfarin, heparin, or thrombolytic agents
• Known brain metastases that are untreated, symptomatic, or require therapy
• Pregnancy, lactation, or breastfeeding